Lyell Immunopharma has reported new clinical data from the Phase I/II clinical trial of CAR T-cell product candidate, LYL314.

Ventyx Biosciences has reported encouraging top-line outcomes from its Phase IIa trial of VTX3232 for early-stage Parkinson's ...

Clarametyx Biosciences has received approval from the Independent DMC to progress its Phase Ib/IIa trial of CMTX-101 ...

This space already includes two approved CAR T-cell therapies: Johnson & Johnson/Legend’s Carvykti and Bristol Myers Squibb’s ...

The US FDA has approved Ocugen’s IND amendment to commence a Phase II/III pivotal confirmatory study of OCU410ST.

Data presented at EHA 2025 demonstrated that the Epkinly / R-ICE combination produced an 87% ORR in transplant-eligible r/r ...

Astria Therapeutics has reported encouraging initial outcomes from its ongoing ALPHA-SOLAR trial of navenibart for HAE ...

At EHA 2025, the preliminary results from the global, multi-centre open-label non-randomised Phase II RedirecTT-1 clinical ...

Johnson & Johnson (J&J) has reported new outcomes from the Phase II RedirecTT-1 trial of bispecific antibodies, Talvey and ...

Bavarian Nordic has commenced a Phase III trial of its chikungunya vaccine, CHIKV VLP, targeting the paediatric population.

Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...

Ionis Pharmaceuticals has dosed the first subject in the global, randomised Phase III REVEAL trial of investigational ION582.